Related Experiment Video
Updated: Jul 6, 2026
10:26
A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
Published on: June 2, 2015
New anticoagulant agents: direct thrombin inhibitors
Edith A Nutescu1, Nancy L Shapiro, Aimee Chevalier
1Department of Pharmacy Practice, Antithrombosis Center, University of Illinois at Chicago, College of Pharmacy and Medical Center, 833 South Wood Street, M/C 886, Room 164, Chicago, IL 60612, USA. enutescu@uic.edu
Cardiology Clinics
|April 15, 2008
Summary
Direct thrombin inhibitors (DTIs) offer safer and more predictable anticoagulation than traditional agents. Research is advancing oral DTIs for convenient, effective blood clot prevention.
Area of Science:
- Pharmacology
- Hematology
- Drug Development
Background:
- Traditional anticoagulants like heparin and warfarin have limitations.
- Direct thrombin inhibitors (DTIs) offer improved safety and efficacy.
- DTIs target both circulating and clot-bound thrombin.
Purpose of the Study:
- To review the development and advantages of direct thrombin inhibitors (DTIs).
- To highlight the benefits of DTIs over conventional anticoagulants.
- To discuss the potential of oral DTIs in anticoagulation therapy.
Main Methods:
- Literature review of anticoagulant research.
- Analysis of DTI mechanisms and clinical benefits.
- Comparison of injectable and oral DTI characteristics.
Main Results:
- DTIs provide predictable anticoagulant response without cofactor dependence.
- DTIs inhibit thrombin-induced platelet aggregation and thrombocytopenia.
- Oral DTIs demonstrate promising advantages including convenience and fixed dosing.
Conclusions:
- Direct thrombin inhibitors represent a significant advancement in anticoagulant therapy.
- Oral DTIs offer a promising, convenient alternative to existing treatments.
- Further research into oral DTIs is warranted for widespread clinical application.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.